Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 17/20 | 0.82 |
| ▸ | BCL2L1 | Q07817 | 17/20 | 0.82 |
| ▸ | BAD | Q92934 | 4/20 | 0.82 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.82 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.82 |
| ▸ | ASPH | Q12797 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25646590 | 0.94 | BCL2 (0.82) | BCL2BCL2L1BADBCL2L2BCL2L11 | |
| SCHEMBL20812412 | 0.93 | BCL2L1 (0.87) | BCL2BCL2L1BADBCL2L2BCL2L11 | |
| SCHEMBL26779298 | 0.93 | BCL2 (0.81) | BCL2BCL2L1BADBCL2L2BCL2L11 | |
| SCHEMBL21179208 | 0.91 | BCL2L1 (0.86) | BCL2BCL2L1BADBCL2L2BCL2L11 | |
| SCHEMBL29695619 | 0.91 | BCL2L1 (0.86) | BCL2BCL2L1BADBCL2L2BCL2L11 | |
| SCHEMBL21179210 | 0.91 | BCL2L1 (0.86) | BCL2BCL2L1BADBCL2L2BCL2L11 | |
| SCHEMBL24985389 | 0.90 | BCL2 (0.86) | BCL2BCL2L1BADBCL2L2BCL2L11 | |
| SCHEMBL19145093 | 0.90 | BCL2L1 (0.93) | BCL2BCL2L1BADBCL2L2BCL2L11 | |
| SCHEMBL19145101 | 0.90 | BCL2L1 (0.93) | BCL2BCL2L1BADBCL2L2BCL2L11 | |
| SCHEMBL1628701 | 0.90 | BCL2 (0.86) | BCL2BCL2L1BADBCL2L2BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | BCL2 2848/4885BCL2L1 2508/4885BAD 3785/4885 |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | BCL2 788/4885BCL2L1 588/4885BAD 1292/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | BCL2 1370/4885BCL2L1 1327/4885BAD 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.